Calif. Pay-For-Delay Law Lacks Nuance
In January, the state of California enacted its new legislation, A.B. 824, making reverse payment patent settlements associated with Hatch-Waxman Act pharmaceutical litigation — or pay-for-delay settlements — presumptively anti-competitive.[1]...To view the full article, register now.
Already a subscriber? Click here to view full article